Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Cream, (US RLD - Temovate® Cream), 0.05%. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such as allergic reactions, eczema, and psoriasis.
The group now has 222 approvals and has so far filed over 330 ANDAs since the commencement ofthe filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.380.75 as compared to the previous close of Rs. 382.95. The total number of shares traded during the day was 87148 in over 1277 trades.
The stock hit an intraday high of Rs. 387.5 and intraday low of 375.6. The net turnover during the day was Rs. 33380222.